ASCT Vs CART for Patients with Relapsed LBCL in PR: Role of TMTV

2][3][4][5][6] However, the optimal management for patients who achieve a partial response (PR) remains debated.In a recently published retrospective registry study, 222 patients with LBCL who received ASCT in PR were compared with 126 patients in PR who received CART, with a significantly lower relapse/progression rate observed in the former. 7owever, in addition to including patients who were not restaged after bridging therapy, the study did not account for differences in baseline tumor burden before ASCT or CART, because the total metabolic tumor volume (TMTV) may significantly vary among patients with PR, and prior studies have revealed that high TMTVs can negatively affect the patient's response to CART. 8